How hMSCs Are Helping Power Organ-On-A-Chip Science

The FDA's 2025 Roadmap to Reducing Animal Testing signals a fundamental shift toward human-based preclinical models, with organ-on-a-chip (OOC) technology positioned to address the stark reality that 90% of drugs fail during clinical trials. Human mesenchymal stromal cells are emerging as versatile biological components within these microfluidic platforms, capable of forming mineralized bone niches, supporting vascularization, and modulating immune responses in ways that capture authentic human physiology. Recent applications demonstrate their range: from bone marrow-on-a-chip systems that evaluate CAR-T therapy efficacy in multiple myeloma to autonomous bioreactors functioning aboard the International Space Station.

Learn how spatial bioprinting techniques now enable precise placement of MSC spheroids within chip architectures, creating reproducible tissue interfaces. These advances address critical gaps in traditional animal models while establishing standardized, scalable platforms for drug development. As regulatory agencies and standards organizations align behind New Approach Methodologies, the convergence of primary human cells with engineered microsystems offers a path toward more predictive, ethical, and industrially viable preclinical testing.